Which one is more effective, Gilteritinib or venetoclax?

Gilteritinib and venetoclax (Venetoclax) are two drugs used to treat hematological malignancies. They have different mechanisms of action and application fields. They have different applications in different leukemia types and gene mutation states. Which one is better depends on the individual patient's situation and usually needs to be decided by the clinician based on detailed condition and patient characteristics. Giritinib is a tyrosine kinase inhibitor mainly used to treat acute myeloid leukemia (AML), especially patients with FLT3-ITD or FLT3-TKD mutations. Venetoclax is a BCL-2 inhibitor mainly used to treat chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).